首页膀胱肿瘤治疗及预后证据详情

Pioglitazone Use and Risk of Bladder Cancer: A Systematic Literature Review and Meta-Analysis of Observational Studies

原文: 2017 年 发布于 Minerva Urol Nefrol 浏览量:159次

作者: Hoti F. Mehtala J. Khanfir H. Christopher S. Bennett D. Ye Y. Z. Korhonen P.

作者单位: Department of Nephrology, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, 315010 China. 2Department of Epidemiology, School of Public Health, Southern Medical University (Guangdong Provincial Key Laboratory of Tropical Disease Research), Guangzhou, 510000 China. ISNI: 0000 0000 8877 7471. GRID: grid.284723.8 3Department of Epidemiology and Population Health, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461 USA. ISNI: 0000000121791997. GRID: grid.251993.5

归属分类: 膀胱肿瘤治疗及预后证据

DOI: 10.1080/2090598x.2020.1841538

文献简介

Background:Previous studies have investigated the relationship between GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and bladder cancer (BCa) susceptibility, respectively, but the results remain inconsistent. So, we conducted this meta-analysis including 79 case-control studies to explore such relationships.Methods:We searched PubMed, EMBASE, Cochrane library, Web of Science, and CNKI for relevant available studies. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were implemented to evaluate the intensity of associations. Publication bias was estimated using Begg funnel plots and Egger regression test. To assess the stability of the results, we used sensitivity analysis with the method of calculating the results again by omitting 1 single study each time. Between-study heterogeneity was tested using the I-2 statistic.Results:No significant association between GSTA1 polymorphism and BCa susceptibility (OR=1.05, 95% CI 0.83-1.33) was noted. Besides, meaningful association between individuals who carried the GSTM1 null genotype and increased BCa risk was detected (OR=1.39, 95%CI 1.28-1.51). When stratified by ethnicity, significant difference was found in both Caucasian (OR=1.39, 95% CI 1.23-1.58) and Asian populations (OR=1.45, 95% CI 1.31-1.61). Moreover, in the subgroup analysis by source of controls (SOC), the results were significant in both hospital-based control groups (OR=1.49, 95% CI 1.35-1.64) and population-based control groups (OR=1.21, 95% CI=1.07-1.37). Additionally, the analysis revealed no significant association between GSTP1 polymorphism and BCa risk (OR=1.07, 95% CI 0.96-1.20). What is more, significant associations between GSTT1 polymorphism and BCa susceptibility were discovered (OR=1.11, 95% CI 1.00-1.22). In the subgroup analysis by ethnicity, significant associations between GSTT1 null genotype and BCa risk were observed only in Caucasians (OR=1.25, 95% CI 1.09-1.44). Furthermore, when stratified by SOC, no obvious relationship was found between the GSTT1 null genotype polymorphism with hospital-based population (OR=1.11, 95% CI 0.97-1.28) or population-based population (OR=1.10, 95% CI 0.96-1.27).Conclusion:This study suggested that GSTM1 null genotype and GSTT1 null genotype might be related to higher BCa risk, respectively. However, no associations were observed between GSTA1 or GSTP1 polymorphisms and BCa susceptibility.

热门文献